BioCentury | Apr 15, 2021
Politics, Policy & Law

Georgia biotech leaders support voting rights, resist calls to shun their state

Biotech industry leaders in Georgia, ground zero for the voting rights controversy, expressed solidarity with the ideas expressed in a letter signed by biotech leaders supporting voting rights, but opposed their calls to consider shunning...
BioCentury | Apr 14, 2021

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...
BioCentury | Apr 10, 2021
Product Development

MD Anderson AACR data in heavily pretreated lymphoma patients offer long-awaited lift to Affimed

Affimed has been working on NK cell engagers since before T cell engagers became popular but the latest data — which catapulted Affimed over the $1 billion market cap threshold — suggest the approach is...
BioCentury | Apr 7, 2021
Product Development

As Scholar Rock readies for SMA Phase III, investors shed shares amid varied durability data

Scholar Rock is moving apitegromab (SRK-015) into Phase III this year, but the myostatin blocker is proving to have a more durable effect in some spinal muscular atrophy patient cohorts than others. The company’s stock...
BioCentury | Mar 30, 2021

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

SomaLogic Inc. is merging with CM Life Sciences II, a SPAC sponsored by Casdin Capital and Corvex Management (NASDAQ:CMIIU). The deal is expected to give the proteomics company up to $651 million in cash, including $375...
BioCentury | Mar 28, 2021

Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO

Less than three months after revealing its series A round, preclinical start-up Biomea Fusion has filed for a NASDAQ listing to fund development of its first irreversible small-molecule cancer therapy, a menin inhibitor that the company...
BioCentury | Mar 25, 2021
Emerging Company Profile

Asher Bio: aiming cytokine therapies at specific immune cells

Asher Bio emerged from stealth Tuesday with a $55 million series A led by Third Rock and a platform to improve the safety and efficacy of cytokine therapies for cancer.  Boxer Capital, Invus and seed...
BioCentury | Mar 22, 2021

Crossovers back Aura with $80M as it preps first pivotal test of virus-like particle conjugation tech

An $80 million crossover series E round will support 12-year-old Aura’s first pivotal trial based on its virus-like particle conjugation technology: a Phase III study in choroidal melanoma, an ocular cancer.  CEO Elisabet de los...
BioCentury | Mar 16, 2021

March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more

Insitro Inc. said existing investor Canada Pension Plan Investment Board led its new $400 million series C round, which builds on a $143 million series B closed in May 2020. Also backing the machine learning-guided drug...
BioCentury | Mar 15, 2021

Versant-built gene editing company Graphite speeds clinical plans with crossover-laden $150M series B

Crossover investors have poured into Graphite’s $150 million series B round six months after the gene therapy company’s launch based on technology out of the Stanford lab of Matthew Porteus, setting it on a quick path...
Items per page:
1 - 10 of 1012